AUM Biosciences Pte. Ltd. ("AUM"), a clinical-stage biotechnology company, advancing a clinical stage candidate and a broader pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer
–Data suggest SINTAX™ medicine may overcome blood-brain barrier limitations to anti-inflammatory drug delivery–
–EDP1867 reduced disease severity and incidence of relapse in murine model of